JP2016505017A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016505017A5 JP2016505017A5 JP2015552797A JP2015552797A JP2016505017A5 JP 2016505017 A5 JP2016505017 A5 JP 2016505017A5 JP 2015552797 A JP2015552797 A JP 2015552797A JP 2015552797 A JP2015552797 A JP 2015552797A JP 2016505017 A5 JP2016505017 A5 JP 2016505017A5
- Authority
- JP
- Japan
- Prior art keywords
- diffraction pattern
- powder diffraction
- peak
- ray powder
- angle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- 239000013078 crystal Substances 0.000 claims description 11
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 10
- 102100036869 Diacylglycerol O-acyltransferase 1 Human genes 0.000 claims description 8
- 101000927974 Homo sapiens Diacylglycerol O-acyltransferase 1 Proteins 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 238000001757 thermogravimetry curve Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229960003194 meglumine Drugs 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 description 4
- 238000000034 method Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361751443P | 2013-01-11 | 2013-01-11 | |
| US61/751,443 | 2013-01-11 | ||
| PCT/US2014/011005 WO2014110344A1 (en) | 2013-01-11 | 2014-01-10 | Meglumine salt forms of 2-((1 r,4r)-4-(4-(5-(benzoxazol-2-ylamino)pyridin-2-yl)phenyl)cyclohexyl) acetic acid and their use as dgat1 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016505017A JP2016505017A (ja) | 2016-02-18 |
| JP2016505017A5 true JP2016505017A5 (enExample) | 2016-12-15 |
| JP6302937B2 JP6302937B2 (ja) | 2018-03-28 |
Family
ID=50001335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015552797A Expired - Fee Related JP6302937B2 (ja) | 2013-01-11 | 2014-01-10 | ２−（（１ｒ，４ｒ）−４−（４−（５−（ベンゾオキサゾール−２−イルアミノ）ピリジン−２−イル）フェニル）シクロヘキシル）酢酸のメグルミン塩形態、およびｄｇａｔ１阻害剤としてのそれらの使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8987459B2 (enExample) |
| EP (1) | EP2943488B1 (enExample) |
| JP (1) | JP6302937B2 (enExample) |
| KR (1) | KR20150103747A (enExample) |
| CN (1) | CN104995188B (enExample) |
| AR (1) | AR101523A1 (enExample) |
| AU (1) | AU2014205276B2 (enExample) |
| BR (1) | BR112015016370A2 (enExample) |
| CA (1) | CA2896861A1 (enExample) |
| EA (1) | EA027688B1 (enExample) |
| ES (1) | ES2675398T3 (enExample) |
| MX (1) | MX2015008978A (enExample) |
| PL (1) | PL2943488T3 (enExample) |
| PT (1) | PT2943488T (enExample) |
| TR (1) | TR201808198T4 (enExample) |
| WO (1) | WO2014110344A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2943488T3 (pl) * | 2013-01-11 | 2018-09-28 | Novartis Ag | Postacie soli megluminowej kwasu 2-((1r,4r)-4-(4-(5-(benzoksazol-2-iloamino)pirydyn-2-ylo)fenylo)cykloheksylo)octowego i ich zastosowania jako inhibitory dgat1 |
| KR101684053B1 (ko) * | 2015-01-20 | 2016-12-08 | 씨제이헬스케어 주식회사 | 벤즈이미다졸 유도체의 신규 결정형 및 이의 제조방법 |
| AU2019255233A1 (en) * | 2018-04-17 | 2020-11-26 | Cardurion Pharmaceuticals, Llc | Meglumine salts of thienopyrimidines |
| WO2022099431A1 (en) * | 2020-11-10 | 2022-05-19 | Unity Biotechnology, Inc. | Crystalline solid meglumine salt inhibitor of bcl and methods of making and using same |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
| RU2456273C2 (ru) * | 2006-03-31 | 2012-07-20 | Новартис Аг | Новые соединения |
| WO2013169648A1 (en) * | 2012-05-07 | 2013-11-14 | Novartis Ag | Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug |
| PL2943488T3 (pl) * | 2013-01-11 | 2018-09-28 | Novartis Ag | Postacie soli megluminowej kwasu 2-((1r,4r)-4-(4-(5-(benzoksazol-2-iloamino)pirydyn-2-ylo)fenylo)cykloheksylo)octowego i ich zastosowania jako inhibitory dgat1 |
-
2014
- 2014-01-10 PL PL14701273T patent/PL2943488T3/pl unknown
- 2014-01-10 BR BR112015016370A patent/BR112015016370A2/pt not_active IP Right Cessation
- 2014-01-10 EP EP14701273.6A patent/EP2943488B1/en not_active Not-in-force
- 2014-01-10 EA EA201591300A patent/EA027688B1/ru not_active IP Right Cessation
- 2014-01-10 ES ES14701273.6T patent/ES2675398T3/es active Active
- 2014-01-10 JP JP2015552797A patent/JP6302937B2/ja not_active Expired - Fee Related
- 2014-01-10 TR TR2018/08198T patent/TR201808198T4/tr unknown
- 2014-01-10 KR KR1020157021323A patent/KR20150103747A/ko not_active Ceased
- 2014-01-10 PT PT147012736T patent/PT2943488T/pt unknown
- 2014-01-10 US US14/152,282 patent/US8987459B2/en not_active Expired - Fee Related
- 2014-01-10 AU AU2014205276A patent/AU2014205276B2/en not_active Ceased
- 2014-01-10 CA CA2896861A patent/CA2896861A1/en not_active Abandoned
- 2014-01-10 MX MX2015008978A patent/MX2015008978A/es unknown
- 2014-01-10 WO PCT/US2014/011005 patent/WO2014110344A1/en not_active Ceased
- 2014-01-10 CN CN201480003867.0A patent/CN104995188B/zh not_active Expired - Fee Related
- 2014-01-13 AR ARP140100113A patent/AR101523A1/es unknown
-
2015
- 2015-02-24 US US14/630,624 patent/US9242971B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017505293A5 (enExample) | ||
| JP2017518334A5 (enExample) | ||
| JP2016535795A5 (enExample) | ||
| JP2016525102A5 (enExample) | ||
| JP2012508734A5 (enExample) | ||
| JP2013519675A5 (enExample) | ||
| JP2017527578A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| JP2010132677A5 (enExample) | ||
| JP2014505107A5 (enExample) | ||
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| JP2015500223A5 (enExample) | ||
| JP2016522254A5 (enExample) | ||
| JP2016510326A5 (enExample) | ||
| JP2016539157A5 (enExample) | ||
| JP2015510916A5 (enExample) | ||
| JP2019501879A5 (enExample) | ||
| JP2016537338A5 (enExample) | ||
| PH12015501945A1 (en) | Formulations of organic compounds | |
| CN115315423A (zh) | 取代芳基类化合物 | |
| JP2016505017A5 (enExample) | ||
| BR112015016184A2 (pt) | derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| JP2009501745A5 (enExample) | ||
| JP2012501334A5 (enExample) | ||
| JP2011524362A5 (enExample) |